

## **Presentation at the Annual Biotech in Europe Investor Forum**

**29 September 2010 in Zurich**

**Paris, 27 September 2010** – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments, is to participate at the 10<sup>th</sup> Annual Biotech in Europe Investor Forum organised by Sachs Associates on 29 and 30 September.

At the event, Hybrigenics's management team will provide details of the major strategic advances made during the current year, in particular the definitive results obtained in the Phase IIa trials of inecalcitol, its flagship product.

Hybrigenics's participation at this key event in the calendar of the European biotechnology industry reflects the Company's commitment to strengthening its relations with investors and raising its profile in the financial community.

\*\*\*

### **About Hybrigenics**

Hybrigenics SA ([www.hybrigenics.com](http://www.hybrigenics.com)) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of cancer. Hybrigenics' development program is based on inecalcitol, a vitamin D analogue, for the treatment of hormone-refractory prostate cancer in combination with Sanofi-Aventis' Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Hybrigenics' research program explores the role of enzymes known as ubiquitin-specific proteases (USP) in the degradation of onco-proteins, and the effectiveness of proprietary USP inhibitors in treating various types of cancer.

Hybrigenics Services SAS is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

**HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris**

**ISIN: FR0004153930**

**Ticker: ALHYG**



**Hybrigenics**  
Rémi Delansorne  
CEO  
Tel.: +33 (0)1 58 10 38 00  
[investors@hybrigenics.com](mailto:investors@hybrigenics.com)

**NewCap.**  
Financial communication  
Axelle Vuillermet / Pierre Laurent  
Tel.: +33 (0)1 44 71 94 94  
[hybrigenics@newcap.fr](mailto:hybrigenics@newcap.fr)